Pharmacology pharmacovigilance bioscience
Review the background and clinical data (meta-data, Table 2) for the new drug candidate, Exault. Analyse and interpret the Adverse Event (AE) data (Table 2) for safety signals, evaluate which signals are ADRs and recommend which signals should be included in ADRs of the Summary of Product Characteristics (SmPC) for Exault.